WeTrials
Recruiting

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With an Open-label Extension Period to Evaluate the Efficacy and Safety of Telitacicept in Patients With Generalized Myasthenia Gravis

What is this study?

This study is testing an experimental medicine called telitacicept to see if it safely and effectively helps people with generalized myasthenia gravis, a condition that causes muscle weakness. Researchers want to find a new way to calm down the overactive immune system that causes these muscle symptoms.

Who can participate?

You might be able to join if you are 18 or older and have a confirmed diagnosis of generalized myasthenia gravis with moderate to severe muscle weakness. Your blood tests must show specific antibodies, and you should not have certain other health issues like active infections or a history of recent cancer.

What will happen?

Participants will be randomly chosen to receive either the study drug telitacicept or a placebo, which looks like the medicine but has no active ingredients. You will be closely monitored by the study team through regular check-ups and physical strength tests to see how well the treatment works.

Where and when?

This study is currently recruiting participants at locations in Scottsdale, Arizona, as well as Los Angeles and Orange, California. Researchers will guide you through the exact schedule and visit requirements at your chosen location.

Key Points
  • 1Testing telitacicept for generalized myasthenia gravis
  • 2Compares the study drug against an inactive placebo
  • 3Currently recruiting participants at select U.S. locations

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Generalized Myasthenia Gravis

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.